@prefix dcterms: .
@prefix this: .
@prefix sub: .
@prefix prov: .
@prefix pav: .
@prefix orcid: .
@prefix codebase: .
@prefix version: .
@prefix instance: .
@prefix process: .
@prefix np: .
@prefix rdfs: .
@prefix xsd: .
@prefix has-source: .
@prefix d: .
@prefix dv: .
@prefix dr: .
@prefix npx: .
sub:head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:publicationInfo;
a np:Nanopublication .
}
sub:assertion {
d:DB01285 dv:ddi-interactor-in dr:DB01285_DB06717 .
d:DB06717 dv:ddi-interactor-in dr:DB01285_DB06717 .
dr:DB01285_DB06717 dcterms:identifier "drugbank_resource:DB01285_DB06717";
dcterms:title "DDI between Corticotropin and Fosaprepitant - Fosaprepitant may increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect. The manufacturer of fosaprepitant states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone.1 Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen. Monitor for increased effects of systemic corticosteroids when coadmininistered with fosaprepitant or aprepitant."@en;
a dv:Drug-Drug-Interaction;
rdfs:label "DDI between Corticotropin and Fosaprepitant - Fosaprepitant may increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect. The manufacturer of fosaprepitant states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone.1 Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen. Monitor for increased effects of systemic corticosteroids when coadmininistered with fosaprepitant or aprepitant. [drugbank_resource:DB01285_DB06717]"@en .
}
sub:provenance {
sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 .
}
sub:publicationInfo {
sub:signature.MCwCFHF5sWsleeos npx:hasPublicKey "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";
npx:hasSignature "MCwCFHF5sWsleeosCYQoMFcnVmrUMadyAhQFUm4bcl46AsiT1kn2aXQw8gxAGQ==";
npx:signedBy instance: .
this: dcterms:created "2018-03-30T11:12:40.514+02:00"^^xsd:dateTime;
dcterms:license ;
npx:hasSignatureElement sub:signature.MCwCFHF5sWsleeos;
prov:wasGeneratedBy process: .
instance: prov:specializationOf codebase:;
prov:wasAttributedTo orcid:0000-0002-1267-0234 .
process: dcterms:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11";
prov:used version:;
prov:wasAssociatedWith instance:;
prov:wasStartedBy orcid:0000-0002-1267-0234 .
version: dcterms:isVersionOf codebase:;
pav:version "eda7951a5f6c622c5d2132f50c3093138484a349";
prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}